Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

  title={Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.},
  author={James M. Sanders and Marguerite L. Monogue and Tomasz Z. Jodlowski and James B. Cutrell},
Importance The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. Observations No proven… 

Tables from this paper

COVID-19: The Immune Responses and Clinical Therapy Candidates
The general features of SARS-CoV-2’s molecular and immune pathogenesis are summarized and available pharmacological strategies are discussed, based on the present understanding of Sars-Cov and Middle East respiratory syndrome coronavirus (MERS- coV) infections.
COVID-19: A review of the proposed pharmacological treatments
Treatments for COVID-19: emerging drugs against the coronavirus
This brief review focuses on the latest and most promising pharmacological treatments against COVID-19 currently under investigation and discuss their potential use based on either documented efficacy in similar viral infections, or their activity against inflammatory syndromes.
Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review
This review aimed to classify and summarize several medications and potential therapies according to the disease 3 stages; however, it is worth noting that no medication and therapy has been effective so far.
An updated review of potential therapeutic agents against COVID-19
Dexamethasone, convalescent plasma therapy, tocilizumab, remdesivir, and combination therapies are found to be beneficial against SARS-CoV-2.
Characteristics and Therapeutic Options of the Coronavirus Disease 2019
Precision therapeutic targets for COVID-19
It is proposed that a multi-drug cocktail targeting precise proteins, critical to the viral replication cycle, such as spike protein, M Pro , and RdRp, will be the most effective strategy of inhibiting SARS-CoV-2 replication and limiting its spread in the general population.
Potential role for nitazoxanide in treating SARS-CoV-2 infection
High-quality trial evidence on nitazoxanide in the treatment of SARS-CoV-2 infection is urgently needed, as theoretical considerations are reasonable and there is potential for in vitro activity against coronaviruses but controlled clinical trials evaluating the safety and efficacy are still lacking.
Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options


New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
Hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach and is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation.
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option
The literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, is discussed, so that the potential for the use ofLPV in patientswith COVID‐19 is clarified.
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
This article summarizes agents with potential efficacy against SARS-CoV-2 and indicates some promising results have been achieved thus far.
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China.
Broad-spectrum coronavirus antiviral drug discovery
In this review, approaches that antagonize viral nonstructural proteins, neutralize structural proteins, or modulate essential host elements of viral infection with varying levels of efficacy in models of highly pathogenic coronavirus disease are discussed.
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • Xueting Yao, F. Ye, Dongyang Liu
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
It is proposed that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients.